Gedatolisib is approved, now comes the commercial launch
- The FDA approved gedatolisib, branded REVTORPYK, for PIK3CA wild-type HR-positive, HER2-negative advanced breast cancer.
- NCCN updated its guidelines to recommend REVTORPYK regimens as preferred Category 1 treatments.
- Management set the wholesale price at $30,000 per cycle and estimates a total addressable market over $6 billion.
- Positive PIK3CA mutant data gives Celcuity a path to a supplemental NDA in the third quarter of 2026.
- A recent $575 million convertible note offering extends the expected cash runway into 2029.
Approval changed the bet
Celcuity has officially transitioned from a pure clinical-stage company to a commercial entity. The key drug is gedatolisib, now branded REVTORPYK. The FDA approved it ahead of schedule for adults with HR-positive, HER2-negative, locally advanced or metastatic breast cancer without a PIK3CA mutation. Shortly after, NCCN updated its guidelines to recommend it as a preferred Category 1 regimen.
The bull case is now fully focused on a massive market opportunity. The primary wild-type approval is secured and de-risked. Management set the wholesale acquisition cost at $30,000 per cycle and expanded its total addressable market estimate to over $6 billion. With cash runway secured through 2029 via a recent $575 million convertible note offering, the company is fully funded for a strong commercial launch.
The bear case also changed. The biggest binary FDA risk for the first label is gone, but execution and supply chain risks are now front and center. Launching an infused drug in a competitive community oncology setting is difficult. Celcuity must win payer coverage, educate oncologists, manage safety concerns, and secure FDA clearance for a second manufacturing site to prevent supply bottlenecks when commercial shipments begin in late Q3 2026.
One approved drug, funded through 2029
Celcuity is transitioning to its first product revenue stream. Its business is to commercialize REVTORPYK through its oncology sales team while continuing development for wider indications. The company generates revenue through the commercial sale of REVTORPYK, which has a wholesale acquisition cost of $30,000 per cycle.
Following a June 2026 convertible note offering that raised large net proceeds, the company reported cash and investments that should fund operations and commercial launch activities into 2029. That extended runway is important because the company is paying for commercial ramp-up and ongoing Phase 3 trials.
The model relies heavily on physician adoption and securing targeted gross-to-net pricing yields around 80 percent. It breaks if doctors do not prescribe REVTORPYK at scale, if payers restrict access, or if early supply chain bottlenecks limit product availability.
Gedatolisib carries the company
REVTORPYK, gedatolisib in PIK3CA wild-type breast cancer
This is the approved lead product and the near-term revenue source. The label covers use with fulvestrant, with or without palbociclib, and has NCCN Category 1 backing.
VIKTORIA-1 PIK3CA mutant expansion
The mutant cohort reported positive topline Phase 3 results. Celcuity plans to submit a supplemental NDA in the third quarter of 2026 to expand the label.
VIKTORIA-2 first-line breast cancer program
This Phase 3 program tests gedatolisib earlier in treatment. Study 1 data are expected by the end of 2028, while the endocrine-sensitive Study 2 expects data by 2030.
CELC-G-201 in metastatic castration-resistant prostate cancer
This Phase 1b/2 trial studies gedatolisib with darolutamide in mCRPC. Updated data for the 300mg dose is expected in the fourth quarter of 2026.
Subcutaneous gedatolisib formulation
Celcuity is developing an under-the-skin version of gedatolisib. The goal is to make multi-year treatment duration easier in future indications.
No revenue mix yet
Celcuity reports one integrated business focused on cancer therapy research, development, and commercialization. The company has not generated revenue and has no reportable product or geography segments.
What can still break
Launch fails to convert approval into sales
High impact · Medium oddsThe first FDA approval removes one major risk, but it does not prove doctors will use the drug widely. Celcuity must teach oncologists where REVTORPYK fits and compete against established breast cancer drugs. A slow launch would raise doubts about the new $6 billion market estimate.
Supply chain bottlenecks
High impact · Medium oddsReliance on FDA clearance for a second manufacturing site presents a near-term supply chain risk. If regulatory sign-off is delayed, supply could be constrained early in the commercial launch phase.
Payers limit access and pricing yield
High impact · Medium oddsCancer drugs can be approved but still face strict insurance rules. Celcuity set pricing at $30,000 per cycle and targets an 80 percent gross-to-net yield. If insurers require many prior steps before covering REVTORPYK or demand steep rebates, revenue will lag.
Mutant-cohort filing delays
Medium impact · Low oddsThe PIK3CA mutant cohort has positive topline data, but Celcuity still needs to file a supplemental NDA in Q3 2026. Any delay in submission or FDA review would slow the path to a wider label.
In one breath
What does Celcuity sell?
Celcuity sells REVTORPYK, the brand name for gedatolisib. It is an FDA-approved breast cancer drug for a defined HR-positive, HER2-negative advanced breast cancer population.
Why is the stock still risky after FDA approval?
Approval lowers regulatory risk for the first label, but it does not guarantee strong sales. The company still needs payer coverage, doctor adoption, clean supply chain execution, and a successful launch.
What is the next big Celcuity catalyst?
The next key items are the initial commercial shipments of REVTORPYK in late Q3 2026 and the planned supplemental NDA submission for PIK3CA mutant patients in the same quarter.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- August 16, 2026
- Score data
- September 6, 2026
- Reviewed by
- Shivam Bharuka
Comparable Biotechnology companies
Companies near Celcuity Inc. in Finn's Biotechnology industry ranking.
